Cancer Biomarkers in United States Trends and Forecast
The future of the cancer biomarkers market in United States looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2031 with a CAGR of 14.5% from 2025 to 2031. The cancer biomarkers market in United States is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the increasing inclination towards personalized medicine for cancer treatment, the growing awareness of the importance of early detection of cancer, and the rising government support for cancer research.
• Lucintel forecasts that, within the cancer type category, breast cancer will remain the largest segment over the forecast period due to the increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
• Within the application category, the diagnostic will remain the largest segment due to the increasing prevalence of cancer and the growing availability of cancer screening programs.
Emerging Trends in the Cancer Biomarkers Market in United States
The United States cancer biomarkers market is in a revolutionary phase, driven by technological innovation, growing demand for personalized medicine, and emerging regulatory policies. As the healthcare industry evolves, new biomarkers, particularly in genomics and liquid biopsy, are improving early detection, diagnosis, and treatment of cancer. With increasing partnerships between research centers, private organizations, and healthcare organizations, the United States is emerging as a world leader in using biomarker technologies to introduce novel cancer therapies. The following are five trends that are redefining the future of the United States’ cancer biomarkers market.
• Development of Liquid Biopsy: Liquid biopsy technology, an incisionless diagnostic technique, is gaining momentum in the United States. By detecting cancer-related genetic mutations, this technology offers a new alternative to conventional biopsies that can be performed more quickly and with reduced pain. Liquid biopsy is particularly useful in monitoring disease progression and detecting minimal residual disease, facilitating early detection. As liquid biopsy gains acceptance and is incorporated into clinical practice, its use in cancer diagnosis and individualized therapy continues to expand, offering significant advantages for patients and healthcare systems alike.
• Integration of Artificial Intelligence in Diagnostics: Artificial intelligence (AI) is now emerging as a pillar of cancer diagnostics in the United States, enabling quicker and more precise identification of cancer biomarkers. AI algorithms can review large sets of patient data, such as genetic data, imaging, and clinical history, uncovering hidden patterns that may be undetectable by human clinicians. The incorporation of AI streamlines cancer diagnosis, leading to more accurate and efficient treatments. As machine learning algorithms advance, AI will increasingly contribute to developing more precise cancer biomarker detection, enhancing patient outcomes, and minimizing diagnostic errors.
• Individualized and Targeted Therapy: Personalized medicine, fueled by the discovery of targeted cancer biomarkers, is revolutionizing cancer treatment in the United States. By analyzing a patient’s genetic makeup and tumor mutations, medical professionals can provide more targeted therapies that match individual requirements. This strategy not only improves the effectiveness of treatment but also reduces the side effects of standard therapies. As genomic sequencing technologies become increasingly affordable and accessible, the shift towards personalized cancer therapy will expand, offering patients increasingly tailored and efficient treatment plans.
• Growth of Early Cancer Detection Programs: In the United States, early detection of cancer has become a key goal in reducing cancer-related deaths. Biomarker-based early detection programs for high-risk cancers such as breast, colon, and lung cancer are increasing, enabling earlier treatment and improving survival rates. These programs utilize biomarkers to detect cancers before symptoms appear, improving detection rates while lowering treatment costs. As the need for more accurate and effective screening methods grows, biomarker-based early detection is likely to become a standard practice in cancer care nationwide.
• Support for Regulation and Innovation: The FDA has stepped up efforts to expedite the approval of new cancer biomarkers and diagnostic technologies. Through programs like the Breakthrough Devices Program and the Precision Medicine Initiative, the FDA is facilitating faster development of new biomarker tests and treatments. This regulatory assistance allows quicker market entry for innovative solutions, fostering a more competitive and dynamic cancer biomarkers market. As regulations evolve, cancer biomarker innovation will be accelerated, defining the future of cancer care in the U.S.
The U.S. cancer biomarkers market is undergoing dramatic change with breakthroughs in liquid biopsy, AI-driven diagnostics, personalized medicine, early detection initiatives, and regulatory support. These trends are reshaping the market through enhanced accuracy in cancer detection, increased treatment options, and improved patient care. As these advancements continue to evolve, they are set to transform cancer treatment, enabling more effective, efficient, and personalized care.
Recent Developments in the Cancer Biomarkers Market in United States
The cancer biomarkers market in United States has experienced significant growth in recent years, with technological advances, research partnerships, and healthcare reforms driving innovation. These trends are accelerating the adoption of new biomarkers for cancer diagnosis, detection, and treatment, leading to better patient outcomes. As the market further develops, major innovations are transforming the cancer care landscape, opening the door for more targeted and efficient treatment strategies. Below are five recent updates in the U.S. cancer biomarkers market.
• FDA Approval of Liquid Biopsy Tests: The U.S. Food and Drug Administration (FDA) has recently approved several liquid biopsy tests to identify genetic mutations and track cancer progression. These diagnostic tests provide a minimally invasive alternative to standard biopsies, delivering quicker and more convenient diagnostic options. For example, the approval of the Guardant360 liquid biopsy test for multiple cancer types has been a significant milestone. This advancement has paved the way for broader clinical use of liquid biopsy, including earlier detection and monitoring of cancer at various stages.
• Breakthroughs in AI-Powered Cancer Diagnostics: AI diagnostic systems for cancer biomarker detection have gained immense popularity in the U.S., making detection faster and more accurate. AI algorithms, including deep learning for medical images and genomics, have achieved advanced levels of accuracy in detecting cancer. AI systems can now process large patient datasets, revealing subtle biomarker patterns that may not be detected through manual observation. This technology reduces diagnostic errors, accelerates treatment decisions, and improves outcomes, making AI an indispensable innovation in the U.S. cancer biomarkers market.
• Genomic Profiling Advances for Cancer: Genomic profiling technologies have made significant progress in the U.S., providing more detailed information about the genetic makeup of cancers. Companies such as Tempus and Foundation Medicine have developed advanced profiling tests to help physicians identify genetic mutations causing cancer. These advancements have transformed cancer treatment, enabling more personalized and targeted therapies. With insights into a patient’s tumor-specific genetic mutations, healthcare providers can design more effective treatments, improving patient outcomes and reducing side effects.
• Expansion of Biomarker-Based Screening Programs: Biomarker-based screening programs are growing in the U.S., enabling earlier cancer detection. Biomarkers are now used in high-risk cancer programs such as breast, colorectal, and lung cancer to detect potential cases before symptoms develop. Government-sponsored screening programs with biomarkers are enhancing early diagnosis and treatment, leading to higher survival rates. The increasing use of biomarker-based screenings will reduce long-term healthcare costs by detecting cancers earlier and at more treatable stages.
• Stepped-up Investment in Cancer Biomarker Research: Investment in cancer biomarker research has risen significantly in the U.S., with government bodies, research institutions, and private companies contributing substantial funding to the development and discovery of new biomarkers. This increased investment has accelerated research and development, leading to new innovations and biomarker tests. These investments are expected to expand the range of available cancer biomarkers, making early detection and targeted treatments more widely accessible and improving patient care.
Recent developments in the cancer biomarkers market in United States, including FDA approvals, AI integration, genomic profiling advances, biomarker-based screening, and increased investments in research, are significantly reshaping cancer diagnosis and treatment. These advancements are improving early detection, enabling personalized therapies, and enhancing patient outcomes, paving the way for a promising future in cancer care in the U.S.
Strategic Growth Opportunities for Cancer Biomarkers Market in United States
The cancer biomarkers market in United States presents immense opportunities for growth in early detection, tailored treatments, and technology-driven diagnostics. With advances in genomics, liquid biopsy, artificial intelligence, and regulatory support, there are several key areas where growth can be strategically leveraged. By focusing on major applications like genomic profiling, AI-based diagnostics, and expanding screening programs, the market can expand significantly. Below are five strategic growth opportunities in the U.S. cancer biomarkers market.
• Genomic Profiling for Personalized Cancer Therapies: Genomic profiling is set to become a key tool for personalized cancer treatment in the U.S. By identifying genetic mutations in both the tumor and the patient, healthcare professionals can develop targeted therapies based on individual needs. This approach minimizes the risk of harmful side effects while maximizing treatment effectiveness. As genomic sequencing technology becomes more accessible and affordable, the market for genomic profiling will grow rapidly, particularly in oncology facilities and research organizations. Personalized cancer treatments are expected to drive growth in genomic profiling services throughout the U.S.
• Growth of Liquid Biopsy Applications: Liquid biopsy technologies are gaining rapid popularity in the U.S., offering a non-invasive alternative to conventional biopsies. These procedures can detect cancer-associated genetic mutations and monitor disease progression using blood samples. As the technology evolves, the number of cancers that can be detected and tracked using liquid biopsy continues to increase. This expansion is particularly important for cancers that are difficult to biopsy, such as lung and pancreatic cancers. The growing clinical adoption of liquid biopsy will redefine cancer diagnostics and monitoring in the U.S.
• AI-Powered Cancer Diagnostic Solutions: Artificial intelligence (AI) is transforming the detection and analysis of cancer biomarkers. AI algorithms can analyze vast amounts of data, such as medical images, genomics, and patient records, to identify patterns that indicate the presence of cancer biomarkers. The ability of AI to enhance diagnostic precision and efficiency is driving its adoption in clinical settings. As AI technologies advance, they will become essential tools for oncologists, creating a significant growth opportunity in the U.S. cancer biomarkers market.
• Expansion of Biomarker-Based Screening Programs: Biomarker-based screening programs represent a major growth area in the U.S., especially for high-risk cancers like breast, colorectal, and lung cancer. By detecting cancer markers in symptom-free patients, these programs enable early intervention and improve survival rates. U.S. government and healthcare organizations are increasing efforts to expand these screening programs to a larger population. With rising demand for early detection, the use of biomarker-based screenings will be a key driver of growth in the cancer biomarkers market.
• Regulatory Support for Groundbreaking Biomarker Tests: The U.S. regulatory environment, particularly through the FDA’s programs like the Breakthrough Devices Program, provides strong support for the development and commercialization of groundbreaking cancer biomarker tests. The FDA’s expedited approval process for promising diagnostic tests enables faster market entry for new technologies. As regulatory support continues to drive innovation, the development of new biomarker-based tests will spur growth in the cancer biomarkers market. This favorable regulatory climate will play a crucial role in the rapid expansion of innovative biomarker diagnostics and therapies in the U.S.
The cancer biomarkers market in the United States holds tremendous opportunities for growth in genomic profiling, liquid biopsy, AI-driven diagnostics, screening programs, and regulatory support. These growth opportunities are optimizing cancer detection and treatment, while also shaping the future of precision and personalized medicine in cancer care. As these opportunities materialize, the U.S. cancer biomarkers market will experience significant growth, leading to improved patient outcomes and advancements in the fight against cancer.
Cancer Biomarkers Market in United States Driver and Challenges
Various technological, economic, and regulatory drivers influence the U.S. cancer biomarkers market. Market growth is fueled by advancements in genomics, AI, and liquid biopsy technologies, while increased investment in cancer research is also driving innovation. However, the market faces challenges, including the high cost of biomarker development, regulatory hurdles, and difficulties in incorporating new technologies into clinical practice. Understanding these drivers and challenges is essential for navigating the evolving world of cancer biomarkers and improving patient outcomes.
The factors responsible for driving the cancer biomarkers market in United States include:
• Advances in Biomarker Detection Technology: New technologies in cancer biomarker detection, such as liquid biopsy and artificial intelligence, have improved the speed and accuracy of cancer diagnosis. Liquid biopsy, for instance, allows non-invasive monitoring of cancer development and identification of minimal residual disease. AI software enhances the processing of medical imaging and genomic data, enabling quicker identification of cancer biomarkers. These technologies are driving market growth by providing more accurate, patient-specific treatment strategies and improving the efficiency of cancer care.
• Increasing Demand for Personalized Medicine: Personalized medicine is a key driver for the cancer biomarkers market, as treatments are increasingly tailored to individual genetic profiles. Advances in genomic profiling allow clinicians to match patients with the best therapy based on their specific genetic mutations. This approach offers better treatment outcomes, fewer side effects, and improved patient care. The growing demand for personalized cancer therapies is fueling the creation and implementation of new cancer biomarkers, further driving the market.
• Growing Investment in Cancer Research: Public and private sector investment in cancer research is driving the cancer biomarkers market. Government agencies, research institutions, and pharmaceutical companies are investing heavily in the discovery of new biomarkers and the development of diagnostic and therapeutic solutions. This investment has led to significant advancements in cancer diagnosis, enabling earlier detection and more targeted treatments. With continued investment, the cancer biomarkers market is expected to grow substantially in the coming years.
• Support for Regulating Innovative Biomarker Solutions: Regulatory agencies, such as the FDA, are providing substantial support for the development and approval of new cancer biomarkers and diagnostic tests. Initiatives like the Breakthrough Devices Program expedite the approval of promising technologies, allowing them to reach the market more quickly. Regulatory assistance fosters innovation and investment in new biomarker-based solutions. As regulatory frameworks evolve, the U.S. market will continue to expand in innovative cancer diagnostics and therapies.
• Expansion of Cancer Screening Programs: Biomarker-based cancer screening programs are growing in the U.S., increasing early detection and treatment of various cancers. These programs target high-risk populations and use biomarkers to detect cancer in asymptomatic patients. By identifying cancer at earlier stages, these screenings improve survival rates and reduce healthcare costs. The expansion of biomarker-based screening programs will support the growth of the cancer biomarkers market by enabling earlier diagnosis and timely interventions.
Challenges in the cancer biomarkers market in United States are:
• High Development Costs of Biomarkers in the U.S.: The high cost of developing and commercializing new biomarkers is a significant challenge for the U.S. cancer biomarkers market. The development process is capital-intensive, and regulatory approval of new tests can be time-consuming and expensive. The resulting high costs may limit access to the latest biomarker technologies, particularly in underserved populations or low-resource healthcare settings.
• Regulatory Barriers: Despite regulatory support, the approval process for new cancer biomarkers remains complex and time-consuming. Safety and efficacy testing requirements can slow the introduction of new biomarker-based treatments and diagnostics. The regulatory landscape may also pose challenges for smaller companies or startups with limited resources, potentially hindering innovation and market growth.
• Incorporating New Technologies into Clinical Practice: Integrating new biomarker technologies into clinical practice presents logistical challenges. Clinicians must be trained in the use of new diagnostic tools, and clinical workflows may need to be adjusted to accommodate these innovations. Additionally, the cost of some biomarker tests may limit their adoption, particularly within public healthcare systems. Overcoming these barriers is critical to ensuring the successful integration of biomarkers into cancer care.
The U.S. cancer biomarkers market is shaped by powerful drivers, including technological advancements, personalized medicine, research investment, and regulatory support. However, challenges such as high development costs, regulatory hurdles, and integration issues must be addressed to maximize the market’s potential. As the market continues to evolve, these drivers and challenges will influence its growth trajectory, ultimately enhancing cancer treatment and patient care across the country.
List of Cancer Biomarkers Market in United States Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, cancer biomarkers companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer biomarkers companies profiled in this report include:
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
Cancer Biomarkers Market in United States by Segment
The study includes a forecast for the cancer biomarkers market in United States by type, cancer type, profiling technology, and application.
Cancer Biomarkers Market in United States by Type [Analysis by Value from 2019 to 2031]:
• Protein
• Genetic
• Others
Cancer Biomarkers Market in United States by Cancer Type [Analysis by Value from 2019 to 2031]:
• Lung
• Breast
• Leukemia
• Melanoma
• Colorectal
• Prostate
• Thyroid
• Kidney
• Others
Cancer Biomarkers Market in United States by Profiling Technology [Analysis by Value from 2019 to 2031]:
• Omics
• Imaging
• Immunoassay
• Bioinformatics
• Others
Cancer Biomarkers Market in United States by Application [Analysis by Value from 2019 to 2031]:
• Diagnostics
• R&D
• Prognostics
• Risk Management
• Others
Features of the Cancer Biomarkers Market in United States
Market Size Estimates: Cancer biomarkers in United States market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Cancer biomarkers in United States market size by type, cancer type, profiling technology, and application in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, cancer type, profiling technology, and application for the cancer biomarkers in United States.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer biomarkers in United States.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q.1 What are the major drivers influencing the growth of the cancer biomarkers market in United States?
Answer: The major drivers for this market are the increasing inclination towards personalized medicine for cancer treatment, the growing awareness of the importance of early detection of cancer, and the rising government support for cancer research.
Q2. What are the major segments for cancer biomarkers market in United States?
Answer: The future of the cancer biomarkers market in United States looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets.
Q3. Which cancer biomarkers market segment in United States will be the largest in future?
Answer: Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 10 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the cancer biomarkers market in United States by type (protein, genetic, and others), cancer type (lung, breast, leukemia, melanoma, colorectal, prostate, thyroid, kidney, and others), profiling technology (omics, imaging, immunoassay, bioinformatics, and others), and application (diagnostics, R&D, prognostics, risk management, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.4. What are the business risks and competitive threats in this market?
Q.5. What are the emerging trends in this market and the reasons behind them?
Q.6. What are some of the changing demands of customers in the market?
Q.7. What are the new developments in the market? Which companies are leading these developments?
Q.8. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.9. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.10. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Cancer Biomarkers Market in United States, Cancer Biomarkers Market in United States Size, Cancer Biomarkers Market in United States Growth, Cancer Biomarkers Market in United States Analysis, Cancer Biomarkers Market in United States Report, Cancer Biomarkers Market in United States Share, Cancer Biomarkers Market in United States Trends, Cancer Biomarkers Market in United States Forecast, Cancer Biomarkers Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.